Distinct binding determinants for ERK2/p38alpha and JNK map kinases mediate catalytic activation and substrate selectivity of map kinase phosphatase-1
- PMID: 11278799
- DOI: 10.1074/jbc.M010966200
Distinct binding determinants for ERK2/p38alpha and JNK map kinases mediate catalytic activation and substrate selectivity of map kinase phosphatase-1
Abstract
Mitogen-activated protein (MAP) kinase phosphatase 1 (MKP-1/CL100) is an inducible nuclear dual specificity protein phosphatase that can dephosphorylate and inactivate both mitogen- and stress-activated protein kinases in vitro and in vivo. However, the molecular mechanism responsible for the substrate selectivity of MKP-1 is unknown. In addition, it has been suggested that the signal transducers and activators of transcription 1 (STAT1) transcription factor is a physiological non-MAP kinase substrate for MKP-1. We have used the yeast two-hybrid assay to demonstrate that MKP-1 is able to interact selectively with the extracellular signal-regulated kinase 1/2 (ERK1/2), p38alpha, and c-Jun NH(2)-terminal kinase (JNK) MAP kinase isoforms. Furthermore, this binding is accompanied by catalytic activation of recombinant MKP-1 protein in vitro, and these end points show an absolute correlation with MKP-1 substrate selectivity in vivo. In contrast, MKP-1 does not interact with STAT1. Recombinant STAT1 does not cause catalytic activation of MKP-1; nor does MKP-1 block tyrosine phosphorylation of STAT1 in vivo. Both binding and catalytic activation of MKP-1 are abrogated by mutation of a conserved docking site in ERK2, p38alpha, and JNK1 MAP kinases. Within MKP-1, MAP kinase binding is mediated by the amino-terminal noncatalytic domain of the protein. However, mutation of a conserved cluster of positively charged residues within this domain abolishes the binding and activation of MKP-1 by ERK2 and p38alpha but not JNK1, indicating that there are distinct binding determinants for these MAP kinase isoforms. We conclude that the substrate selectivity of MKP-1 is determined by specific protein-protein interactions coupled with catalytic activation of the phosphatase and that these interactions are restricted to members of the MAP kinase family of enzymes.
Similar articles
-
Catalytic activation of mitogen-activated protein (MAP) kinase phosphatase-1 by binding to p38 MAP kinase: critical role of the p38 C-terminal domain in its negative regulation.Biochem J. 2000 Nov 15;352 Pt 1(Pt 1):155-63. Biochem J. 2000. PMID: 11062068 Free PMC article.
-
Discordance between the binding affinity of mitogen-activated protein kinase subfamily members for MAP kinase phosphatase-2 and their ability to activate the phosphatase catalytically.J Biol Chem. 2001 Aug 3;276(31):29440-9. doi: 10.1074/jbc.M103463200. Epub 2001 May 31. J Biol Chem. 2001. PMID: 11387337
-
The mitogen-activated protein kinase phosphatase-3 N-terminal noncatalytic region is responsible for tight substrate binding and enzymatic specificity.J Biol Chem. 1998 Apr 10;273(15):9323-9. doi: 10.1074/jbc.273.15.9323. J Biol Chem. 1998. PMID: 9535927
-
Regulation of innate immune response by MAP kinase phosphatase-1.Cell Signal. 2007 Jul;19(7):1372-82. doi: 10.1016/j.cellsig.2007.03.013. Epub 2007 Apr 20. Cell Signal. 2007. PMID: 17512700 Free PMC article. Review.
-
Dual-specificity phosphatases: critical regulators with diverse cellular targets.Biochem J. 2009 Mar 15;418(3):475-89. doi: 10.1042/bj20082234. Biochem J. 2009. PMID: 19228121 Review.
Cited by
-
Analysis of the effect of CCR7 on the microenvironment of mouse oral squamous cell carcinoma by single-cell RNA sequencing technology.J Exp Clin Cancer Res. 2024 Mar 27;43(1):94. doi: 10.1186/s13046-024-03013-y. J Exp Clin Cancer Res. 2024. PMID: 38539232 Free PMC article.
-
MAPK phosphatase 1 inhibition of p38α within lung myofibroblasts is essential for spontaneous fibrosis resolution.J Clin Invest. 2024 Mar 21;134(10):e172826. doi: 10.1172/JCI172826. J Clin Invest. 2024. PMID: 38512415 Free PMC article.
-
Hepatocyte-specific mitogen-activated protein kinase phosphatase 1 in sexual dimorphism and susceptibility to alcohol induced liver injury.Front Immunol. 2024 Feb 1;15:1316228. doi: 10.3389/fimmu.2024.1316228. eCollection 2024. Front Immunol. 2024. PMID: 38370409 Free PMC article.
-
CSGALNACT2 restricts ovarian cancer migration and invasion by modulating MAPK/ERK pathway through DUSP1.Cell Oncol (Dordr). 2024 Jun;47(3):897-915. doi: 10.1007/s13402-023-00903-9. Epub 2023 Dec 12. Cell Oncol (Dordr). 2024. PMID: 38082211 Free PMC article.
-
BCI, an inhibitor of the DUSP1 and DUSP6 dual specificity phosphatases, enhances P2X7 receptor expression in neuroblastoma cells.Front Cell Dev Biol. 2022 Dec 15;10:1049566. doi: 10.3389/fcell.2022.1049566. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36589747 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous